Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
+0.07 (2.23%)
May 20 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 3.16 - 3.50
52 week 2.30 - 5.34
Open 3.50
Vol / Avg. 5,801.00/7,443.00
Mkt cap 108.26M
P/E     -
Div/yield     -
EPS -0.58
Shares 32.29M
Beta 2.99
Inst. own     -
Aug 9, 2016
Q2 2016 Aurinia Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 11, 2016
Q1 2016 Aurinia Pharmaceuticals Inc Earnings Release
Mar 18, 2016
Q4 2015 Aurinia Pharmaceuticals Inc Earnings Release
Mar 7, 2016
Aurinia Pharmaceuticals Inc at Cowen Health Care Conference

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -7485.97% -7917.87%
Operating margin -8503.51% -10034.04%
EBITD margin - -9371.06%
Return on average assets -55.83% -43.30%
Return on average equity -95.11% -69.13%
Employees 26 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board
Age: 57
Charles A. Rowland Jr. Chief Executive Officer, Director
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
Benjamin Rovinski Ph.D. Independent Director
Age: 58